Full-Time

Senior Specialist

Security Operations

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma leveraging fermentation and antibodies

Compensation Overview

$115k - $130k/yr

No H1B Sponsorship

Princeton, NJ, USA

Hybrid

Hybrid role; up to 10% travel domestically and internationally.

US Citizenship, US Top Secret Clearance, Canada Citizenship, Canada Top Secret Clearance, UK Citizenship, UK Top Secret Clearance Required

Category
IT & Security (1)
Required Skills
Malware Analysis
Vulnerability Analysis
Requirements
  • Education: Bachelor’s degree in Information Security, Computer Science, or related field required; Advanced training in OT/ICS security preferred.
  • Certifications Required: CISSP
  • Experience: At least 5 years in cybersecurity operations, with demonstrated experience in SOC or incident response leadership; Strong hands on experience with OT/ICS environments in pharma, biotech, manufacturing, or critical infrastructure; Expertise in SIEM, SOAR, forensic tools, and threat detection engineering; Knowledge of OT security frameworks (ISA/IEC 62443, NIST CSF) and pharmaceutical regulations (GxP, HIPAA, 21 CFR Part 11).
  • Technical Skills: Expertise in Security Operations and Incident Response, including triage, investigation, containment, and recovery across IT, cloud, and OT environments; Hands-on experience with SOC technologies such as SIEM, SOAR, EDR/XDR, and forensic analysis platforms; Strong background in OT/ICS cybersecurity, including SCADA, PLCs, and lab systems, with application of frameworks such as ISA/IEC 62443 and NIST CSF; Knowledge of threat detection engineering, use-case development, and integration of threat intelligence into monitoring workflows; Proficiency in forensic tools and malware analysis to support root-cause identification and post-incident review; Understanding of regulatory compliance requirements including GxP, HIPAA, and 21 CFR Part 11, as they apply to manufacturing and research systems; Experience collaborating on vulnerability management, patching, and remediation across IT and OT environments.
Responsibilities
  • Lead incident response for North America, coordinating with the global SOC for escalations, investigations, and recovery.
  • Manage monitoring solutions to ensure high-quality visibility across IT, cloud, and OT environments.
  • Own OT/ICS cybersecurity strategy in partnership with manufacturing, infrastructure, and plant leadership, securing SCADA, PLCs, and lab systems.
  • Vendor management for proactive threat hunting, pen testing and forensic analysis.
  • Lead remediation activities for both IT and OT environments.
  • Drive regional execution of global SOC playbooks, escalation models, and threat intelligence integration.
  • Develop and maintain operational security runbooks and ensure continuous improvement of detection and response capabilities.
  • Partner with IT, R&D, and Manufacturing to enforce regulatory compliance across GxP, HIPAA, and FDA-controlled systems.
Desired Qualifications
  • Advanced training in OT/ICS security preferred.
  • GICSP, GRID, or other OT-focused certifications

Kyowa Kirin is a global specialty pharmaceutical company that develops medicines using fermentation and antibody technologies. Its products target areas like nephrology, oncology, and immunology, with therapies built from biologics and other drug modalities. The company emerged from a merger between Kyowa Hakko Kogyo and Kirin Pharma, combining Kyowa’s fermentation and microbiology expertise with Kirin’s pharma resources to create a worldwide focus on specialty drugs. Unlike broader drug companies, Kyowa Kirin concentrates on a defined set of indications and runs a research-and-development-led business that aims to deliver innovative treatments for patients in need.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Simplify Jobs

Simplify's Take

What believers are saying

  • Libmeldy commercialization in MLD expands rare disease revenue streams globally.
  • Orchard pipeline programs in MPS, FTD, Crohn's disease address high unmet needs.
  • North Carolina manufacturing capacity supports cell and gene therapy market growth.

What critics are saying

  • Libmeldy reimbursement denial in UK, Germany, US collapses primary revenue driver.
  • Orchard pipeline failures in Phase 2/3 trials eliminate $478M acquisition rationale.
  • Gene therapy manufacturing delays at Sanford facility constrain supply and revenue ramp.

What makes Kyowa Kirin unique

  • 75+ years fermentation expertise underpins proprietary antibody and gene therapy platforms.
  • Orchard Therapeutics acquisition adds Libmeldy gene therapy for rare genetic diseases.
  • $530M Sanford biologics facility enables scaled manufacturing of advanced cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Kyowa Kirin who can refer or advise you

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.